Author of

• 34876

  +

  P02 - Diagnostics and Interventional Pulmonology (ID 110)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Diagnostics and Interventional Pulmonology
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 34911

    +

    P02.20 - Does Response at 1st Scan Imaging After Any Line Correlate With PFS? (ID 1942)

    00:00 - 00:00  |  Presenting Author(s): FADI Nasr
    • Abstract
    • Slides

    Introduction
    

    The objectives of this study are first to investigate the prediction of non-small cell lung cancer (NSCLC) patient survival outcomes based on the first imaging results following any line of therapy and second, to check if this correlation is impacted by the type of treatment used, immunotherapy versus chemotherapy.

    Methods
    

    Of the 60 patients in our institution whose data was collected, 29 eligible NSCLC patients were included in our retrospective analysis. These are the NSCLC patients whose imaging results after completing a new line of therapy were available in our institution. Imaging modalities used for evaluation included thoraco-abdominopelvic CT with IV contrast or 18-FDG PET-CT scan. Imaging was performed after between 4 and 6 cycles of chemotherapy, after chemotherapy-immunotherapy combination, or after immunotherapy alone. Response on imaging was defined as partial, progressive, stable, or complete at each line. Analysis was performed according to line of treatment (1^st, 2^nd, or 3^rd). Progression free survival (PFS) was defined as the duration of time from the start of the treatment until progression of disease. Overall survival (OS) was defined as the duration of time from diagnosis to death related to disease.

    Results
    

    Of the 29 patients of median age 73, 93% were men and 7% were women. First line was comprised of 51.7%, 17.2%, 27.6% chemotherapy, immunotherapy, and chemotherapy-immunotherapy combination respectively. After first line treatment, 29.6%, 40.7%, and 29.6% of patients respectively achieved partial, progressive, and stable response on imaging. No complete response was achieved in the first line. For first line of therapy, a significantly shorter PFS 1 duration was found in those who had a progressive response on scan (HR=2.36; p=0.036). Concerning the second line of therapy, a significantly longer PFS 2 duration was found in those who had a partial response (HR=0.03; p=0.002), stable response (HR=0.01; p=0.01) and complete response (HR=0.01; p=0.01) on scan for second line after adjustment over the type of treatment (chemotherapy, chemotherapy-immunotherapy combination, immunotherapy). There is no correlation between OS and response on imaging after any line.

    Conclusion
    

    Progressive response on first imaging results after therapy in both the first line and the second, irrespective of the type of therapy, was correlated with shorter a PFS1 and PFS2 in NSCLC patients.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.